|
KaloBios shares tank on failed asthma drug trial
San Francisco Business Times (blog) KaloBios (NASDAQ: KBIO), which has seen its stock price tumble since it raised $70 million in an initial public offering a year ago, will discontinue clinical development of the drug, called KB-003, in severe asthma. The monoclonal antibody was safe … KaloBios to Stop KB003 Development for Asthma KaloBios calls it quits on its asthma drug after a Phase II flop KaloBios Pharma pulls plug on asthma drug, shares plunge |
View full post on asthma – Google News